8-(1,3-dioxolan-2-yl)-7-ethoxy-4-methyl-2H-chromen-2-one | 1238397-35-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 8-(1,3-dioxolan-2-yl)-7-ethoxy-4-methyl-2H-chromen-2-one
• CAS: 1238397-35-7
• 化学式: C₁₅H₁₆O₅
• 分子量: 276.289
• InChiKey: WQVPDWDWECRKDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.55
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.9
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  8-(1,3-dioxolan-2-yl)-7-ethoxy-4-methyl-2H-chromen-2-one 在 盐酸 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 28.0h， 生成 (7-ethoxy-4-methyl-2-oxo-2H-chromen-8-yl)methyl cinnamate
  参考文献：
  名称：

  Seco-4-methyl-DCK derivatives as potent chemosensitizers

  摘要：

  Twenty-five seco-4-methyl-DCK derivatives were designed, synthesized and evaluated for chemoreversal activity when combined with paclitaxel or vincristine in two drug-resistant cancer cell lines (A2780/T and KB-V) respectively. Most of the new compounds displayed moderate to significant MDR reversal activities in the P-gp overexpressing A2780/T and KB-V cells. Especially, compounds 7o and 7y showed the most potent chemosensitization activities with more than 496 and 735 reversal ratios at a concentration of 10 mu M. Unexpectedly the newly synthesized compounds did not show chemosensitization activities observed in a non-P-gp overexpressing cisplatin resistant human ovarian cancer cell line (A2780/CDDP), implying that the MDR reversal effects might be associated with P-gp overexpression. Moreover, these compounds did not exhibit significant antiproliferative activities against nontumorigenic cell lines (HUVEC, HOSEC and T29) compared to the positive control verapamil at the tested concentration, which suggested better safety than verapamil. The pharmacological actions of the compounds will be studied further to explore their merit for development as novel candidates to overcome P-gp mediated MDR cancer.

  DOI：

  10.1016/j.bmcl.2018.11.023
• 作为产物：
  描述：

  羟甲香豆素 在 potassium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 potassium iodide 作用下， 以 丙酮 、 苯 为溶剂， 反应 12.5h， 生成 8-(1,3-dioxolan-2-yl)-7-ethoxy-4-methyl-2H-chromen-2-one
  参考文献：
  名称：

  Seco-4-methyl-DCK derivatives as potent chemosensitizers

  摘要：

  Twenty-five seco-4-methyl-DCK derivatives were designed, synthesized and evaluated for chemoreversal activity when combined with paclitaxel or vincristine in two drug-resistant cancer cell lines (A2780/T and KB-V) respectively. Most of the new compounds displayed moderate to significant MDR reversal activities in the P-gp overexpressing A2780/T and KB-V cells. Especially, compounds 7o and 7y showed the most potent chemosensitization activities with more than 496 and 735 reversal ratios at a concentration of 10 mu M. Unexpectedly the newly synthesized compounds did not show chemosensitization activities observed in a non-P-gp overexpressing cisplatin resistant human ovarian cancer cell line (A2780/CDDP), implying that the MDR reversal effects might be associated with P-gp overexpression. Moreover, these compounds did not exhibit significant antiproliferative activities against nontumorigenic cell lines (HUVEC, HOSEC and T29) compared to the positive control verapamil at the tested concentration, which suggested better safety than verapamil. The pharmacological actions of the compounds will be studied further to explore their merit for development as novel candidates to overcome P-gp mediated MDR cancer.

  DOI：

  10.1016/j.bmcl.2018.11.023

文献信息

• Anti-AIDS agents 82: Synthesis of seco-(3′R,4′R)-3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) derivatives as novel anti-HIV agents
  作者：Jian Tang、Keduo Qian、Bei-Na Zhang、Ying Chen、Peng Xia、Donglei Yu、Yi Xia、Zheng-Yu Yang、Chin-Ho Chen、Susan L. Morris-Natschke

  DOI：10.1016/j.bmc.2010.04.089

  日期：2010.6.15

  value of 0.058 μM and a therapeutic index (TI) of 1000. The activity of 9 was better than that of 4-methyl DCK (2, EC50: 0.126 μM, TI: 301.2) in the same assay. Additionally, 9 also showed antiviral activity against a multi-RT inhibitor-resistant strain (RTMDR), which is insensitive to most DCK analogs. Compared with 2, compound 9 has a less complex structure, fewer hydrogen-bond acceptors, and a reduced

  十三新颖开环DCK类似物（4 - 16）配有几个新的骨架设计，合成和筛选的体外抗HIV-1活性。其中，三种化合物（5，13，和16）显示出中度的活性，和化合物9显示出与EC的最佳活性50 0.058μM的值和治疗指数的1000（TI）的活性9明显优于4-甲基 DCK ( 2 , EC 50 : 0.126 μM, TI: 301.2) 在相同的测定中。此外，9还对多 RT 抑制剂耐药菌株 (RTMDR) 显示出抗病毒活性，该菌株对大多数 DCK 类似物不敏感。与2相比，化合物9的结构更简单，氢键受体更少，log P值降低 。因此，它可能表现出更好的 ADME，并且似乎是作为抗 HIV 候选物进一步开发的有希望的新线索。